share_log

Morgan Stanley Maintains Overweight on Akoya Biosciences, Lowers Price Target to $8

Morgan Stanley Maintains Overweight on Akoya Biosciences, Lowers Price Target to $8

摩根士丹利维持对Akoya Biosciences的增持,将目标股价下调至8美元
Benzinga ·  2023/10/24 08:20

Morgan Stanley analyst Tejas Savant maintains Akoya Biosciences (NASDAQ:AKYA) with a Overweight and lowers the price target from $15 to $8.

摩根士丹利分析师Tejas Savant维持秋谷生物科技(纳斯达克:AKYA)增持,并将目标价从15美元下调至8美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发